TOKYO, Mar 30, 2016 - (ACN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016, as follows:
1. Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)
2. Reason for revision of the consolidated financial results forecasts
- Revenue is forecasted to be Yen547,000 million (down 0.3% from the previous fiscal year) due to the impact of the latest results of the Japan pharmaceutical business and exchange rates.
- Operating profit is forecasted to be Yen51,000 million which is unchanged from the previous forecast as the impact from the decrease in revenue will be offset by further progress in cost optimization.
- Profit for the period is forecasted to be Yen50,000 million (up Yen13,000 million from the previous forecast), attributable to the transfer of shares in AkaRx Inc. by Eisai's U.S. subsidiary Eisai Inc. as announced today.
Furthermore, Eisai intends to set the dividend for the period (second six-month period ending March 31, 2016) at Yen80 per share, with the forecast for the total dividend for the year remaining unchanged at Yen150 per share (same amount as the previous fiscal year).
Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of March 30, 2016.
About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2016 JCN Newswire . All rights reserved.
